Fractyl is a Massachusetts based company who is working on the first procedure to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes. Basically, the procedure is designed to treat the root cause of the disease by resurfacing the damaged lining of the upper intestine (duodenum). The goal is to reset the hormone regulation and improve glucose control with the potential to make type 2 diabetes a treatable digestive disease instead of a lifelong, chronic struggle.

Dr. Harith Rajagopalan is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in Chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science. After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at Harvard Medical School.

Category: Nonprofits & Activism
Uploaded by: Diabetes Hands Foundation
Hosted: youtube